How Should a Life Sciences Startup Think About Insurance at Each Funding Stage?

Insurance is not a one-time purchase for a life sciences startup. It is a program that has to be rebuilt at each funding round, because each round changes what investors require, what contracts demand, and how much risk the company actually carries. The coverage that got a company through seed stage is almost never enough at Series A, and the place that mismatch surfaces is due diligence, when an investor’s counsel reads the program against the company’s stage and finds the gaps.

Seed Stage: The Foundation

At seed stage the program is lean, but lean is not the same as absent. The exposures that exist from day one are the ones tied to early activity: a contract manufacturer or a clinical site that requires evidence of coverage, a first hire, an office lease, and the handling of any data. For a device company, product and clinical-trial exposure can begin well before any clearance, which is why coverage timed to first human use and first shipment, not to the FDA calendar, matters this early. For a digital health company the early exposure is usually data and the first technology service. The goal at seed is to place the lines that real activity demands and to avoid paying for coverage ahead of the exposure, not to build the mature program prematurely. The seed stage gets its own deeper treatment in what insurance a seed-stage life sciences company needs.

Series A: The First Real Restructure

Series A is where the program stops being a formality. Institutional investors take board seats and expect their own exposure covered, which is what makes directors and officers insurance a near-universal Series A requirement, often written straight into the term sheet. For a device company that need is the same reason a device company adds D&O once it has a board or investors. The diligence at this stage is specific: investor counsel examines the lines and limits and reads them against the regulatory profile, the framing walked through in digital health insurance for a Series A raise. This is also the stage where a first enterprise customer often appears, and a health system or payor contract sets its own insurance requirements that the seed-stage program will not meet. The Series A requirements get their own deeper treatment in what investors require at Series A.

The practical failure at Series A is treating insurance as a closing checklist item. D&O placement takes time, the contract requirements take time, and a program that has to be rebuilt during the raise can slow the close. The companies that handle it well right-size the program as the round comes together, not after the redline arrives.

Series B and Beyond: Scaling the Program

By Series B the company has scale, and the program has to scale with it. Headcount drives employment practices exposure. Outside capital and a larger board deepen the D&O exposure. International expansion, more customers, and more data widen cyber and product exposure. The Series A program rarely stretches to cover all of this, which is why a Series B program restructure typically separates lines that were once bundled, adds excess layers, and brings management liability into its own tower. Underwriting also gets more demanding, with carriers asking for the documentation that a mature company is expected to have.

The through-line across all three stages is that the exposure leads and the coverage follows. Each round adds activity, people, contracts, and data, and each addition is a change the program has to absorb on purpose rather than discover at the next diligence.

What to Do Now

Treat every financing as a trigger to review the program, not just the milestone to celebrate. Before a raise, map the new exposures the round will create, the investor requirements, the contract requirements, the new headcount and geographies, and confirm a line answers each. The diligence-stage review of the program is its own discipline, covered in what insurance a life sciences company needs during due diligence. A federal award carries its own insurance conditions, covered in what government contracts require from life sciences companies. Keep the documentation current, because diligence and underwriting both run on it. The cost of getting this wrong is rarely the premium; it is a stalled close or an uncovered claim at the stage the company can least absorb it.

Before your next round, have the program reviewed against the stage you are raising into, not the one you are leaving. A specialty review through Tower Street Insurance can align a life sciences startup’s coverage to what the next round of investors and customers will actually require.